Use of memantine to treat Alzheimer's disease [1]

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 5, 2006, Pages 501-502

  Gauthier, Serge ^a   Herrmann, Nathan ^b   Ferreri, Florian ^c   Agbokou, Catherine ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Allan Memorial Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; LETTER; SOMNOLENCE; VISUAL HALLUCINATION; CANADA; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; RANDOMIZED CONTROLLED TRIAL;

ALZHEIMER DISEASE; CANADA; DOPAMINE AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEMANTINE; RANDOMIZED CONTROLLED TRIALS;

EID: 33748353793     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.1060168     Document Type: Letter

References (10)

1. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006;5(2):160-70.
2. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20: 459-64.
3. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003;348(14):1333-41.
4. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24.
5. Winblad B, Poritis N. Momeantine in severe dementia: results of the 9M-Best Study (Benefit and efficiacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14(2):135-46.
6. Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60(1);110-8.
7. Ebixa, memantine HCl [product monograph]. In: Compendium of pharmaceutical and specialties. Ottawa: Canadian Pharmacists Association; 2006. p. 729-33.
8. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003;18(2):81-5.
9. Gauthier S. Managing discontinuation syndrome in patients with dementia. J Psychiatry Neurosci 2006;31:72.
10. Waldemar G. Tolerability of switching from donepezil treatment in patients with moderate to severe Alzheimer's disease [presentation]. 9th Congress of the European Federation of Neurological Sciences; 2005 Sept 17-20; Athens.